{"public_id":"cl_80c3b3ceaee1a7cd7a98a2511113aef1","status":"active","superseded_by_public_id":null,"corpus_id":7488532,"text":"The levosimendan group had greater decreases in B-type natriuretic peptide level at 24 hours that persisted through 5 days compared with the dobutamine group.","confidence":0.96,"paper":{"corpus_id":7488532,"title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.","url":"https://sah.borca.ai/papers/7488532"},"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.96,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_11cf6a878a29164ab03ad96f61db8e1d","name":"levosimendan group","description":"The randomized group of 664 patients assigned to receive intravenous levosimendan.","types":["study group"],"url":"https://sah.borca.ai/concepts/co_11cf6a878a29164ab03ad96f61db8e1d"},{"public_id":"co_1a171ee9d46b67ff519ca27fe25b4c68","name":"B-type natriuretic peptide level","description":"A plasma biomarker level measured over time after treatment in the trial.","types":["biomarker"],"url":"https://sah.borca.ai/concepts/co_1a171ee9d46b67ff519ca27fe25b4c68"},{"public_id":"co_4ae3a3ad2fd187b2e47335c3b92618ed","name":"dobutamine group","description":"The randomized group of 663 patients assigned to receive intravenous dobutamine.","types":["study group"],"url":"https://sah.borca.ai/concepts/co_4ae3a3ad2fd187b2e47335c3b92618ed"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_80c3b3ceaee1a7cd7a98a2511113aef1"}